21 January 2021 | News
The fully launched MAH and priority review pathways from the NMPA (National Medical Products Administration) is stimulating new demand in China for 2021
The recently hosted CPhI & P-MEC China 2020 – organised by Informa Markets and CCCMHPIE and co-organised by Shanghai Sinoexpo Informa Markets International Exhibition Co, Ltd – attracted a remarkable 46,157 visits of professional pharma visitors, including 5,105 international attendees taking part online.
The hybrid event has helped stimulate renewed growth and partnerships across the pharma supply chain, with the pharma industry looking well positioned for 2021.
The ingredients, machinery and manufacturing sectors reported particularly robust attendance – with full implementation of the Marketing Authorisation Holder (MAH) system, coupled with priority review pathways from the NMPA (National Medical Products Administration) driving much new demand.
In fact, 2,958 companies from the pharma supply chain attended – including Pfizer, Sanofi, Capsugel, Dupont, Merck, BASF, Fosun Pharma, Hengrui Medicine, Yangtze River Pharmaceutical and Fette.
Finally, to celebrate the 20th anniversary of CPhI China, the organising committee awarded a ‘CPhI China 20th Anniversary Founding Exhibitor Award’ and ‘P-MEC China 15th Anniversary Founding Exhibitor Award’ on the opening day at the CPhI China 20th anniversary reception.
For international online attendees, the event teamed up with PharmaSources.com to launch the Virtual Expo Connect (VEC), which ran for a full month in December and connected pharma in China with overseas customers.
“2021 promises to be a celebration of the pharma industry with vaccine distribution now underway and we look forward to helping the industry meet both online and in person so it can continue its work in discovering and delivering vital therapies to patients,” commented Laura Murina, Brand Manager, Informa.
CPhI & P-MEC China 2021 will return to SNIEC (from December 16-18, 2021) with a comprehensive online and offline offering – providing access to vital connections in person and through enhanced digital pharma platforms.